Pfizer's Oral Antiviral Paxlovid Receives FDA Emergency Use Authorization for Mild-to-Moderate COVID-19

Pfizer's anti-COVID-19 oral medication PAXLOVID received emergency use authorization from the U.S. Food and Drug Administration (FDA) on the 22nd local time, for the treatment of patients with mild to moderate symptoms of COVID-19.

According to the review by the Food and Drug Administration, the oral medication produced by Pfizer is currently suitable for patients aged 12 years and above, with a body weight of no less than 40 kilograms. (CCTV reporter Yin Yue, Xu Xiao)